PATENCY-2 trial of vonapanitase to promote radiocephalic fistula use for hemodialysis and secondary patency.

Objective: Arteriovenous fistulas created for hemodialysis often fail to become usable and are frequently abandoned. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in increasing radiocephalic fistula use for hemodialysis and secondary patency.

Methods: PATENCY-2 was a randomized, double-blind, placebo-controlled trial in patients on or approaching the need for hemodialysis undergoing radiocephalic arteriovenous fistula creation.

A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis.

Objective: Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis.

Methods: PATENCY-1 was a double-blind, placebo-controlled trial that enrolled 349 patients on or approaching hemodialysis and being evaluated for radiocephalic arteriovenous fistula creation.

Arteriovenous Fistula Creation by Nephrologist Access Surgeons Worldwide.

Several years ago, we published an article in this journal entitled "Autologous Arteriovenous Fistula Creation by Nephrologists." The goal of that effort was to review outcomes published by nephrologist access surgeons from around the world. An attempt was also made to define the elements that were necessary for successful autologous fistula creation in hopes that they might be used by others in an effort to increase the number of and durability of autologous fistulas in the dialysis population.

Outcomes of arteriovenous fistulae created by a U.S. interventional nephrologist.

Arteriovenous fistulae (AVF) outcomes in the United States continue to fall short of expectations and continue to compare disfavorably to European AVF outcomes. This study presents the early experience of nephrologist created AVF outcomes in the U.S.

Autologous arteriovenous fistula creation by nephrologists.

In 1966, physicians from the Bronx Veterans Administration Hospital, New York City described the surgical creation of a distal radial artery to cephalic vein AV fistula. This novel configuration, for the first time, allowed effective and reproducible cannulation for hemodialysis access and has remained the gold standard for hemodialysis access since. More than 40 years later, vascular access remains the Achilles' heel of hemodialysis therapy.

Role of surgical intervention for cephalic arch stenosis in the "fistula first" era.

Cephalic arch stenosis (CAS) is a frequent cause of vascular access dysfunction in patients with brachiocephalic fistulae. While percutaneous balloon angioplasty has been used to treat CAS, the results of this approach have been poor due to multiple factors including resistant nature of the stenosis, development of early restenosis, as well as poor patency and high vein rupture rates. In this analysis, we report the results of an alternative approach to manage this problem.

Efficiency and outcomes of emergent vascular access procedures performed at a dedicated outpatient vascular access center.

The outpatient vascular access center (VAC) may have an important impact in improving the outcomes of emergent procedures on nonfunctioning hemodialysis access. An emergent procedure is defined as the absence of a functioning access for hemodialysis, including thrombosed graft or fistula, nonfunctioning dialysis catheters, and the need for access to initiate emergent hemodialysis. The aim of this study was to prospectively evaluate the efficiency and outcomes of all consecutive emergent hemodialysis access procedures during a 3-month period at a single high volume VAC.

Pharmacomechanical thrombolysis of natural vein fistulas: reduced dose of TPA and long-term follow-up.

Twenty-five episodes of pharmacomechanical thrombolysis of 20 clotted arteriovenous fistulas (AVFs) are reported. The technique presented utilizes the local instillation of tissue plasminogen activator (TPA) in small doses together with manual maceration to dissolve clot and balloon angioplasty to correct the underlying stenoses. Since the minimum dose of TPA necessary to successfully perform thrombolysis of a natural vein fistula had never been determined, an attempt to use as minimal a dose of TPA as possible was made.